These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3233711)

  • 21. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro.
    Wang Z; Foye A; Chang Y; Chess PR; Wright TW; Bhagwat S; Gigliotti F; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2005 Jun; 288(6):L1124-31. PubMed ID: 15886399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant.
    Walther FJ; Waring AJ; Hernandez-Juviel JM; Gordon LM; Schwan AL; Jung CL; Chang Y; Wang Z; Notter RH
    PLoS One; 2007 Oct; 2(10):e1039. PubMed ID: 17940603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct steps in the adsorption of pulmonary surfactant to an air-liquid interface.
    Walters RW; Jenq RR; Hall SB
    Biophys J; 2000 Jan; 78(1):257-66. PubMed ID: 10620290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy.
    Whitsett JA; Ohning BL; Ross G; Meuth J; Weaver T; Holm BA; Shapiro DL; Notter RH
    Pediatr Res; 1986 May; 20(5):460-7. PubMed ID: 3754957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adsorption of pulmonary surfactant protein SP-A to monolayers of phospholipids containing hydrophobic surfactant protein SP-B or SP-C: potential differential role for tertiary interaction of lipids, hydrophobic proteins, and SP-A.
    Taneva SG; Keough KM
    Biochemistry; 2000 May; 39(20):6083-93. PubMed ID: 10821681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary surfactant function is abolished by an elevated proportion of cholesterol.
    Gunasekara L; Schürch S; Schoel WM; Nag K; Leonenko Z; Haufs M; Amrein M
    Biochim Biophys Acta; 2005 Oct; 1737(1):27-35. PubMed ID: 16216549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins.
    Cockshutt AM; Absolom DR; Possmayer F
    Biochim Biophys Acta; 1991 Sep; 1085(2):248-56. PubMed ID: 1892895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of L
    Fritz JR; Loney RW; Hall SB; Tristram-Nagle S
    Biophys J; 2021 Jan; 120(2):243-253. PubMed ID: 33347885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids.
    Holm BA; Notter RH; Finkelstein JN
    Chem Phys Lipids; 1985 Sep; 38(3):287-98. PubMed ID: 3841303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH
    Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SP-B and SP-C alter diffusion in bilayers of pulmonary surfactant.
    Schram V; Hall SB
    Biophys J; 2004 Jun; 86(6):3734-43. PubMed ID: 15189869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity.
    Günther A; Kalinowski M; Elssner A; Seeger W
    Am J Physiol; 1994 Nov; 267(5 Pt 1):L618-24. PubMed ID: 7977772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics.
    Hall SB; Lu RZ; Venkitaraman AR; Hyde RW; Notter RH
    J Appl Physiol (1985); 1992 May; 72(5):1708-16. PubMed ID: 1601776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Separation of subfractions of the hydrophobic components of calf lung surfactant.
    Hall SB; Wang Z; Notter RH
    J Lipid Res; 1994 Aug; 35(8):1386-94. PubMed ID: 7989863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biophysical Activity of Impaired Lung Surfactant upon Exposure to Polymer Nanoparticles.
    Beck-Broichsitter M
    Langmuir; 2016 Oct; 32(40):10422-10429. PubMed ID: 27641633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible and irreversible inactivation of preformed pulmonary surfactant surface films by changes in subphase constituents.
    Amirkhanian JD; Taeusch HW
    Biochim Biophys Acta; 1993 Jan; 1165(3):321-6. PubMed ID: 8418890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double injection ADSA-CSD methodology for lung surfactant inhibition and reversal studies.
    Saad SM; Policova Z; Dang A; Acosta EJ; Hair ML; Neumann AW
    Colloids Surf B Biointerfaces; 2009 Oct; 73(2):365-75. PubMed ID: 19586757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins.
    Cockshutt AM; Possmayer F
    Biochim Biophys Acta; 1991 Oct; 1086(1):63-71. PubMed ID: 1954245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structures of pulmonary surfactant films adsorbed to an air-liquid interface in vitro.
    Bachofen H; Gerber U; Gehr P; Amrein M; Schürch S
    Biochim Biophys Acta; 2005 Dec; 1720(1-2):59-72. PubMed ID: 16405864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synchronized changing of transinterface pressure, bubble radius and surface tension: a unique feature of lung surfactant.
    Liu M
    Chem Phys Lipids; 1997 Sep; 89(1):55-65. PubMed ID: 9353902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.